DrugPatentWatch Database Preview
Drugs in Development Information for Ganaxolone
» See Plans and Pricing
What is the development status for investigational drug Ganaxolone?
Ganaxolone is an investigational drug.
There have been 18 clinical trials for Ganaxolone.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.
The most common disease conditions in clinical trials are Epilepsy, Disease, and Seizures. The leading clinical trial sponsors are Marinus Pharmaceuticals, U.S. Army Medical Research and Materiel Command, and INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium.
There are one hundred and twelve US patents protecting this investigational drug and nine hundred and seventy-two international patents.
Summary for Ganaxolone
US Patents | 112 |
International Patents | 972 |
US Patent Applications | 505 |
WIPO Patent Applications | 231 |
Japanese Patent Applications | 93 |
Clinical Trial Progress | Phase 2 (2015-02-01) |
Vendors | 30 |
Recent Clinical Trials for Ganaxolone
Title | Sponsor | Phase |
---|---|---|
RAndomized Therapy In Status Epilepticus | Marinus Pharmaceuticals | Phase 3 |
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) | Marinus Pharmaceuticals | Phase 2 |
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study) | Marinus Pharmaceuticals | Phase 3 |
Clinical Trial Summary for Ganaxolone
Top disease conditions for Ganaxolone
Top clinical trial sponsors for Ganaxolone
US Patents for Ganaxolone
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Ganaxolone | Start Trial | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties | RESEARCH TRIANGLE INSTITUTE (Research Triangle Park, NC) THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC) | Start Trial |
Ganaxolone | Start Trial | Uses of ganaxolone | WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, WI) | Start Trial |
Ganaxolone | Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Start Trial |
Ganaxolone | Start Trial | Sugar ester nanoparticle stabilizers | St. John's University (Queens, NY) | Start Trial |
Ganaxolone | Start Trial | Method of treating organophosphate intoxication by administration of neurosteroids | The Texas A&M University System (College Station, TX) | Start Trial |
Ganaxolone | Start Trial | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration | Sapna Life Sciences Corporation (Burlington, CA) | Start Trial |
Ganaxolone | Start Trial | Anticonvulsant activity of steroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ganaxolone
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Ganaxolone | Australia | AU2008265898 | 2027-06-15 | Start Trial |
Ganaxolone | Canada | CA2698172 | 2027-06-15 | Start Trial |
Ganaxolone | European Patent Office | EP2155204 | 2027-06-15 | Start Trial |
Ganaxolone | Spain | ES2589139 | 2027-06-15 | Start Trial |
Ganaxolone | Japan | JP2010530004 | 2027-06-15 | Start Trial |
Ganaxolone | Japan | JP2015003925 | 2027-06-15 | Start Trial |
Ganaxolone | Japan | JP2015007128 | 2027-06-15 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |